Abstract
Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 423-431 |
| Number of pages | 9 |
| Journal | Therapeutic Drug Monitoring |
| Volume | 38 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Aug 2016 |
Keywords
- cisplatin
- clinical practice recommendations
- hearing loss
- ototoxicity
- pharmacogenetic testing